The Risk of Biopsy-detectable Prostate Cancer Using the Prostate Cancer Prevention Trial Risk Calculator in a Community Setting

Overview

Journal Urol Oncol

Publisher Elsevier

Date 2012 May 4

PMID 22552047

Citations 2

Authors

Yuanyuan Liang

Donna P Ankerst

Ziding Feng

Rong Fu

Janet L Stanford

Ian M Thompson

Affiliations

Soon will be listed here.

Abstract

Materials And Methods: Risks of prostate cancer (CaP) and high-grade CaP were evaluated using the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) in an age-stratified random sample of 1,021 Caucasian and African-American men with no previous diagnosis of CaP, aged 55-74 years, residing in King County, WA, USA.

Results: Median PCPTRC risks of CaP (high-grade CaP) were 15.6% (1.2%), 18.7% (2.0%), 18.5% (2.2%), and 26.4% (5.1%) for 55-59, 60-64, 65-69, and 70-74-year-old men, respectively; 25.2% of men aged 55-59 had a 25% or greater PCPTRC risk of CaP; this increased to 53.1% in men aged 70-74; 9.4% of men aged 55-59 had a 6% or greater PCPTRC risk of high-grade CaP, increasing to 44.1% in men aged 70-74.

Conclusions: PCPTRC risk of CaP in a community of US males is high and confounded with overdetected cancers. In contrast, average community PCPTRC risk of high-grade disease is low and increases gradually by age and may better serve for counseling purposes.

Citing Articles

Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review.

Bandala-Jacques A, Castellanos Esquivel K, Perez-Hurtado F, Hernandez-Silva C, Reynoso-Noveron N JMIR Cancer. 2021; 7(3):e30430.

PMID: 34477564 PMC: 8449298. DOI: 10.2196/30430.

Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.

Watson K, Henderson V, Murray M, Murphy A, Ben Levi J, McDowell T Prog Community Health Partnersh. 2019; 13(5):103-112.

PMID: 31378740 PMC: 6693518. DOI: 10.1353/cpr.2019.0043.

References

Ankerst D, Boeck A, Freedland S, Thompson I, Cronin A, Roobol M . Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2012; 30(2):181-7. PMC: 3616370. DOI: 10.1007/s00345-011-0818-5. View

Liang Y, Messer J, Louden C, Jimenez-Rios M, Thompson I, Camarena-Reynoso H . Prostate cancer risk prediction in a urology clinic in Mexico. Urol Oncol. 2012; 31(7):1085-92. PMC: 3362673. DOI: 10.1016/j.urolonc.2011.12.023. View

Parekh D, Ankerst D, Higgins B, Hernandez J, Canby-Hagino E, Brand T . External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006; 68(6):1152-5. DOI: 10.1016/j.urology.2006.10.022. View

Eyre S, Ankerst D, Wei J, Nair P, Regan M, Bueti G . Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol. 2009; 182(6):2653-8. PMC: 5890334. DOI: 10.1016/j.juro.2009.08.056. View

Ankerst D, Koniarski T, Liang Y, Leach R, Feng Z, Sanda M . Updating risk prediction tools: a case study in prostate cancer. Biom J. 2011; 54(1):127-42. PMC: 3715690. DOI: 10.1002/bimj.201100062. View

Roobol M, Schroder F, Hugosson J, Stephen Jones J, Kattan M, Klein E . Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2011; 30(2):149-55. PMC: 3321270. DOI: 10.1007/s00345-011-0804-y. View

Chun F, De La Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P . Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009; 56(4):659-67. DOI: 10.1016/j.eururo.2009.03.029. View

Nguyen C, Yu C, Moussa A, Kattan M, Stephen Jones J . Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol. 2009; 183(2):529-33. DOI: 10.1016/j.juro.2009.10.007. View

Vickers A, Cronin A, Roobol M, Hugosson J, Stephen Jones J, Kattan M . The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010; 16(17):4374-81. PMC: 2937360. DOI: 10.1158/1078-0432.CCR-10-1328. View

10.

Nam R, Toi A, Klotz L, Trachtenberg J, Jewett M, Appu S . Assessing individual risk for prostate cancer. J Clin Oncol. 2007; 25(24):3582-8. DOI: 10.1200/JCO.2007.10.6450. View

11.

Hernandez D, Han M, Humphreys E, Mangold L, Taneja S, Childs S . Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2008; 103(5):609-14. PMC: 3340925. DOI: 10.1111/j.1464-410X.2008.08127.x. View

12.

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

13.

Stanford J, Wicklund K, McKnight B, Daling J, Brawer M . Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8(10):881-6. View

14.

Cao D, Ye D, Zhang H, Zhu Y, Wang Y, Yao X . A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate. 2010; 71(7):700-10. DOI: 10.1002/pros.21286. View

15.

Agalliu I, Salinas C, Hansten P, Ostrander E, Stanford J . Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008; 168(3):250-60. PMC: 2585510. DOI: 10.1093/aje/kwn141. View

16.

Roobol M, Steyerberg E, Kranse R, Wolters T, van den Bergh R, Bangma C . A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2009; 57(1):79-85. DOI: 10.1016/j.eururo.2009.08.025. View

17.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

18.

Thompson I, Ankerst D, Chi C, Goodman P, Tangen C, Lucia M . Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8):529-34. DOI: 10.1093/jnci/djj131. View

19.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

20.

Chou R, Croswell J, Dana T, Bougatsos C, Blazina I, Fu R . Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155(11):762-71. DOI: 10.7326/0003-4819-155-11-201112060-00375. View